A weight loss pill cut average body weight 11.2 percent in a 72 week trial

Almost every weight loss medicine of the past decade is a peptide, a short chain of amino acids, and almost all of them are injected, because digestion takes chains like that apart. Orforglipron is neither. It is a small molecule, assembled by ordinary chemistry rather than built as a chain, and it is swallowed once a day. Two late stage trials of it have now been published, and together they describe both what the tablet did and what has never been tested [1][2].

Why the chemistry matters

The injected medicines in this field imitate a hormone called GLP-1, so they are shaped like it, which is to say they are chains. A chain has to go under the skin because the gut would digest it. A small molecule does not have that problem, and it can be made in a chemical plant rather than grown, which changes how much of it can exist. Orforglipron reaches the same docking point on the cell, the GLP-1 receptor, from a completely different starting material [1][2].

The trial in adults without diabetes

ATTAIN-1 enrolled 3,127 adults who had obesity and no diabetes, and ran for 72 weeks. Chance decided whether each participant received one of three amounts of the tablet or an inactive tablet, alongside advice on food and activity. The main measurement was percent change in body weight at week 72, counted in a way that keeps every participant in the group they were put into, whether or not they stayed on the tablet [1][4].

Average weight reduction was 7.5 percent on the smallest amount, 8.4 percent on the middle one and 11.2 percent on the largest, against 2.1 percent for the inactive tablet. Within the largest group, 54.6 percent of participants lost at least a tenth of their body weight, 36.0 percent lost at least 15 percent and 18.4 percent lost at least a fifth, against 12.9, 5.9 and 2.8 percent in the comparison group. Waist measurement, blood pressure, triglycerides and non HDL cholesterol also improved more than in the comparison group. Between 5.3 and 10.3 percent of the people taking the tablet stopped because of side effects, against 2.7 percent of the others [1].

The trial in adults who also have type 2 diabetes

ATTAIN-2 ran the same 72 weeks at 136 sites in ten countries and enrolled 1,613 adults who had obesity or overweight together with type 2 diabetes. Average weight reduction was 5.1 percent, 7.0 percent and 9.6 percent across the three amounts, against 2.5 percent for the inactive tablet. Ten deaths were reported during the trial, six among participants taking the tablet and four among those taking the inactive one [2].

That the figures are lower in the second trial will not surprise researchers, since weight tends to move less in people with type 2 diabetes on medicines of this kind. It is also the reason a single headline number attached to a medicine is usually the wrong thing to carry around. Same tablet, same length of trial, two populations, two different answers [1][2].

The comparison that has not been run

No trial has put this tablet against an injected medicine, or against a swallowed peptide. What exists instead is an indirect comparison published in Diabetes, Obesity and Metabolism in 2026. It took participant by participant data from a trial of a swallowed peptide and published summary figures from ATTAIN-1, then adjusted by statistics for differences between the two sets of participants in sex, body weight and blood sugar status [3].

It reported the swallowed peptide ahead on weight reduction by 3.2 percentage points under one count and 3.0 under the other, with ranges of uncertainty reaching 0.4 and 0.3 points at the near end, close to no difference at all. The authors state the caveat themselves [3].

These findings provide insight into the comparative effectiveness and tolerability in the absence of head-to-head clinical trials.

Michalak and colleagues, Diabetes, Obesity and Metabolism, 2026 [3]

Two facts belong next to that sentence. An indirect comparison rests on the assumption that the two trials were alike enough to line up, which no adjustment can fully guarantee. And the paper was written mostly by employees of the company that makes the comparison medicine, with paid contractors and one academic author. Neither fact makes the analysis wrong. Both are reasons it is not the same object as a trial in which the same people were assigned to one medicine or the other [3].

What it does not show

It does not show that the tablet works better or worse than the injections, because that trial does not exist. It does not show anything about heart attacks, strokes or years lived, because neither trial measured them and 72 weeks is too short to. It does not describe what happens to weight after the tablet stops. The registry entry for the first trial, which lists 3,127 participants, still shows the study as active and not recruiting, so parts of it continue past the results already printed [1][4].

What the published record does establish is narrower and still worth knowing. A medicine that is not a peptide, taken by mouth, reduced weight by an average of 11.2 percent over 72 weeks in adults with obesity and by 9.6 percent in adults who also had type 2 diabetes, in trials that compared it with nothing except an inactive tablet [1][2].